Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 3

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 3
---
 ANY RELATED FREE WRITING PROSPECTUS, AND UNDER SIMILAR HEADINGS IN THE OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.

This prospectus may not be used to offer or sell any securities unless accompanied by a prospectus supplement.

As of August 13,
2025, the aggregate market value of our outstanding common stock held by non-affiliates, or public float, was approximately $26.1
million, based on 11,077,705 shares of outstanding common stock held by non-affiliates as of the date of this prospectus, at a price
of $2.36 per share, which was the last reported sale price of our common stock on the NYSE American on August 11, 2025. Pursuant to
General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement of which
this prospectus is a part in a public primary offering with a value exceeding more than one-third of our public float in any
12-month period so long as our public float remains below $75.0 million. As of the date hereof, we have not offered any securities
pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this
prospectus.

The securities may be sold
directly by us to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or
delayed basis. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution”
in this prospectus and in the applicable prospectus supplement. If any agents or underwriters are involved in the sale of any securities
with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions,
discounts and options to purchase additional securities will be set forth in a prospectus supplement. The price to the public of such
securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement.

Neither the U.S. Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this Prospectus is, 2025.

-